Literature DB >> 30913028

The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation.

Olga Vasiljeva1, Daniel R Hostetter1, Stephen J Moore1, Michael B Winter1.   

Abstract

The role of proteases in cancer was originally thought to be limited to the breakdown of basement membranes and extracellular matrix (ECM), thereby promoting cancer cell invasion into surrounding normal tissues. It is now well understood that proteases play a much more complicated role in all stages of cancer progression and that not only tumor cells, but also stromal cells are an important source of proteases in the tumor microenvironment. Among all the proteolytic enzymes potentially associated with cancer, some proteases have taken on heightened importance due to their significant up-regulation and ability to participate at multiple stages of cancer progression and metastasis. In this review, we discuss some of the advances in understanding of the roles of several key proteases from different classes in the development and progression of cancer and the potential to leverage their upregulated activity for the development of novel targeted treatment strategies.

Entities:  

Keywords:  cancer; prodrug; protease; proteolysis; tumor microenvironment

Year:  2019        PMID: 30913028     DOI: 10.1515/hsz-2018-0451

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

1.  A Protease Activatable Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interferon Gamma-Dependent and Interferon Gamma-Independent Mechanisms.

Authors:  Karli Norville; Denise Skrombolas; Shannon L Ferry; Nolan Kearns; John G Frelinger
Journal:  J Interferon Cytokine Res       Date:  2022-07       Impact factor: 3.657

Review 2.  Cysteine Cathepsins in Tumor-Associated Immune Cells.

Authors:  Tanja Jakoš; Anja Pišlar; Anahid Jewett; Janko Kos
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

3.  The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.

Authors:  Thomas Kryza; Nathalie Bock; Scott Lovell; Anja Rockstroh; Melanie L Lehman; Adam Lesner; Janaththani Panchadsaram; Lakmali Munasinghage Silva; Srilakshmi Srinivasan; Cameron E Snell; Elizabeth D Williams; Ladan Fazli; Martin Gleave; Jyotsna Batra; Colleen Nelson; Edward W Tate; Jonathan Harris; John D Hooper; Judith A Clements
Journal:  Mol Oncol       Date:  2019-11-28       Impact factor: 6.603

4.  Macrophage imaging and subset analysis using single-cell RNA sequencing.

Authors:  Sean Arlauckas; Nuri Oh; Ran Li; Ralph Weissleder; Miles A Miller
Journal:  Nanotheranostics       Date:  2021-01-01

5.  Extracellular Vesicles Derived from Acidified Metastatic Melanoma Cells Stimulate Growth, Migration, and Stemness of Normal Keratinocytes.

Authors:  Maxim L Bychkov; Artem V Kirichenko; Irina N Mikhaylova; Alexander S Paramonov; Evgeny V Yastremsky; Mikhail P Kirpichnikov; Mikhail A Shulepko; Ekaterina N Lyukmanova
Journal:  Biomedicines       Date:  2022-03-12

6.  Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.

Authors:  Iñaki Etxeberria; Elixabet Bolaños; Alvaro Teijeira; Saray Garasa; Alba Yanguas; Arantza Azpilikueta; William M Kavanaugh; Olga Vasiljeva; Marcia Belvin; Bruce Howng; Bryan Irving; Kimberly Tipton; James West; Li Mei; Alan J Korman; Emanuela Sega; Irene Olivera; Assunta Cirella; Maria C Ochoa; Maria E Rodriguez; Ana Melero; Miguel F Sanmamed; John J Engelhardt; Ignacio Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

7.  CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.

Authors:  Rachel E Sanborn; Omid Hamid; Elisabeth Ge de Vries; Patrick A Ott; Javier Garcia-Corbacho; Valentina Boni; Johanna Bendell; Karen A Autio; Daniel C Cho; Ruth Plummer; Mark Stroh; Lawrence Lu; Fiona Thistlethwaite
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.